Dermapharm Holding SE

DMP

DE000A2GS5D8

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:17 2024-06-05 am EDT			Pre-market 02:00:07 am
38.35 ^EUR	+2.40%		38.55	+0.52%

08:09am	DERMAPHARM : Jefferies reiterates its Buy rating	ZD
May. 15	Drug manufacturer Dermapharm starts the new year with declines	DP

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

May 18, 2022 at 01:30 am EDT

Dermapharm Holding SE provided earnings guidance for the full year 2022. For the year, the company expected growth in consolidated revenue by 10% to 13% (2021: EUR 942.9 million) and in consolidated EBITDA by 3% to 7% (EUR 351.1 million).

Latest news about Dermapharm Holding SE

DERMAPHARM : Jefferies reiterates its Buy rating	02:09am	ZD
Drug manufacturer Dermapharm starts the new year with declines	May. 15	DP
Dermapharm Holding SE Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
WDH/Pharmaceuticals manufacturer Dermapharm starts the new year with declines	May. 15	DP
DERMAPHARM : Berenberg keeps its Buy rating	Apr. 04	ZD
Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Dpa-AFX Overview: COMPANIES from 14.03.2024 - 15:15	Mar. 14	DP
Dermapharm looks cautiously into the future - missing Covid business	Mar. 14	DP
DERMAPHARM : Berenberg reaffirms its Buy rating	Dec. 07	ZD
DERMAPHARM : Berenberg reiterates its Buy rating	Nov. 16	ZD
Dpa-AFX Overview: COMPANIES from 15.11.2023 - 15:15	Nov. 15	DP
Dermapharm grows thanks to new subsidiary - nutritional supplements in demand	Nov. 15	DP
DERMAPHARM : Jefferies reiterates its Buy rating	Nov. 15	ZD
Dermapharm Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
Dermapharm grows thanks to subsidiary Arkopharma and dietary supplements	Nov. 15	DP
DERMAPHARM : Buy rating from Berenberg	23-10-19	ZD
DERMAPHARM : Berenberg maintains a Buy rating	23-09-21	ZD
Dermapharm Holding SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
DERMAPHARM : Jefferies keeps its Buy rating	23-08-29	ZD
Dermapharm move to SDax top - Jefferies praises profitability	23-08-16	DP
Dermapharm becomes more optimistic after first half-year - share price jumps	23-08-16	DP
Jefferies leaves Dermapharm at 'Buy' - Target 65 euros	23-08-16	DP
DERMAPHARM : Jefferies reiterates its Buy rating	23-08-16	ZD
Dermapharm becomes more optimistic after first half year	23-08-16	DP
Dermapharm Holding SE Provides Earnings Guidance for the Year 2023	23-08-16	CI

Chart Dermapharm Holding SE

Duration

Period

More charts

Company Profile

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

Sector

Pharmaceuticals

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Dermapharm Holding SE

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38.35 EUR

Average target price

54.1 EUR

Spread / Average Target

+41.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DERMAPHARM HOLDING SE	-9.42%	2.24B
ELI LILLY AND COMPANY	+42.69%	749B
NOVO NORDISK A/S	+34.11%	605B
JOHNSON & JOHNSON	-6.87%	351B
MERCK & CO., INC.	+18.74%	328B
ABBVIE INC.	+6.76%	292B
ASTRAZENECA PLC	+18.08%	248B
ROCHE HOLDING AG	-3.44%	214B
NOVARTIS AG	+11.35%	216B
PFIZER, INC.	+2.64%	167B

Other Pharmaceuticals